Teachers Retirement System of The State of Kentucky Has $14.15 Million Holdings in Guardant Health, Inc. $GH

Teachers Retirement System of The State of Kentucky grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 11.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 153,253 shares of the company’s stock after acquiring an additional 15,782 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Guardant Health were worth $14,155,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Alyeska Investment Group L.P. bought a new position in Guardant Health during the third quarter worth $114,421,000. Price T Rowe Associates Inc. MD grew its position in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Norges Bank acquired a new stake in Guardant Health in the 4th quarter worth $128,499,000. Summit Partners Public Asset Management LLC increased its holdings in shares of Guardant Health by 674.5% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock worth $87,019,000 after purchasing an additional 741,958 shares during the period. Finally, Westfield Capital Management Co. LP bought a new position in shares of Guardant Health during the 4th quarter worth about $55,073,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on GH. Barclays increased their target price on shares of Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Morgan Stanley boosted their price target on Guardant Health from $130.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada started coverage on Guardant Health in a report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, Sanford C. Bernstein lifted their price objective on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus target price of $155.70.

Insider Buying and Selling

In related news, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. This trade represents a 4.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12. Following the completion of the sale, the chief executive officer directly owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. This represents a 7.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 708,681 shares of company stock worth $90,566,438. Insiders own 5.60% of the company’s stock.

Guardant Health Stock Down 1.0%

NASDAQ:GH opened at $158.40 on Tuesday. The firm has a market capitalization of $21.00 billion, a PE ratio of -46.73 and a beta of 1.59. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $174.08. The firm has a 50-day moving average price of $128.92 and a 200 day moving average price of $108.75.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.